<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1">
<title>mCRPC Clinical Handbook (ASCO 2025)</title>
<style>
  body {
    font-family: "Trebuchet MS", sans-serif;
    margin: 0;
    background: #f6f8fb;
    color: #1a1a1a;
    line-height: 1.65;
  }
  header {
    background: #0b3d91;
    color: white;
    padding: 24px 16px;
    text-align: center;
  }
  h1 { margin: 0 0 8px; font-size: 1.9rem; }
  .container { max-width: 1000px; margin: auto; padding: 20px; }
  .card {
    background: white;
    border-radius: 12px;
    padding: 20px;
    margin: 22px 0;
    box-shadow: 0 2px 6px rgba(0,0,0,0.07);
  }
  h2 { margin-top: 0; border-left: 5px solid #0b3d91; padding-left: 10px; }
  h3 { color: #0b3d91; margin-top: 18px; }
  .tag { display:inline-block; padding:4px 10px; border-radius:8px; color:white; font-size:0.85rem; margin-right:6px; }
  .arpi { background:#1976d2; } .parpi { background:#2e7d32; } .taxane { background:#d32f2f; }
  .radio { background:#6a1b9a; } .immuno { background:#ff8f00; } .other { background:#455a64; }
  details { border:1px dashed #e5e7eb; border-radius:10px; padding:10px 12px; background:#f9fbff; margin-top:10px; }
  summary { cursor:pointer; font-weight:700; }
  .evidence { background:#eef4ff; border-left:4px solid #0b3d91; border-radius:6px; padding:10px 12px; margin-top:10px; }
  a.doi { color:#0b3d91; text-decoration:none; border-bottom:1px dotted #0b3d91; }
  a.doi:hover { opacity:.8; }
  /* Floating TOC */
  nav {
    position: fixed;
    top: 80px;
    left: 20px;
    width: 220px;
    background: #fff;
    border: 1px solid #e5e7eb;
    border-radius: 8px;
    padding: 12px;
    box-shadow: 0 2px 6px rgba(0,0,0,0.08);
    font-size: 0.9rem;
  }
  nav h4 { margin-top: 0; color:#0b3d91; }
  nav a { display:block; color:#0b3d91; text-decoration:none; margin:6px 0; }
  nav a:hover { text-decoration:underline; }
  .content { margin-left:260px; }
  .foot { color:#666; font-size:.9rem; text-align:center; margin:28px 0; }
</style>
</head>
<body>
<header>
  <h1>mCRPC Clinical Handbook</h1>
  <div>ASCO 2025 • Evidence-based systemic therapy recommendations</div>
</header>

<nav>
  <h4>Contents</h4>
  #introIntroduction</a>
  #biomarkersBiomarkers</a>
  #monitoringMonitoring</a>
  #adt-onlyADT Only</a>
  #adt-arpiADT + ARPI</a>
  #adt-docetaxelADT + Docetaxel</a>
  #tripletTriplet</a>
  #specialSpecial Situations</a>
  #nepcNEPC / AVPC</a>
</nav>

<div class="content">
<div class="container">

<!-- INTRO -->
<section class="card" id="intro">
  <h2>Introduction</h2>
  <p><strong>PSA kinetics (PSADT/velocity):</strong> In mCRPC, PSA kinetics are <em>not</em> used to select therapy; avoid PSA-only progression calls without clinical or imaging evidence.</p>
</section>

<!-- BIOMARKERS -->
<section class="card" id="biomarkers">
  <h2>Biomarkers</h2>
  <details open>
    <summary>HRR genes & BRCA</summary>
    <p>HRR genes include BRCA1/2, PALB2, ATM, CHEK2, CDK12. BRCA1/2 alterations predict strong benefit from PARPi strategies.</p>
  </details>
  <details>
    <summary>MSI-H/dMMR</summary>
    <p>MSI-H/dMMR predicts response to pembrolizumab; rare in prostate cancer but clinically relevant.</p>
  </details>
</section>

<!-- MONITORING -->
<section class="card" id="monitoring">
  <h2>Monitoring Strategy</h2>
  <ul>
    <li><strong>Labs:</strong> PSA, testosterone, CBC, CMP.</li>
    <li><strong>Imaging:</strong> CT CAP + bone scan every 3–6 months or earlier if clinically indicated.</li>
    <li><strong>PSMA PET:</strong> Only for Lu-PSMA eligibility; not routine for response assessment.</li>
  </ul>
</section>

<!-- ADT ONLY -->
<section class="card" id="adt-only">
  <h2>1) Prior CSPC: ADT Only</h2>
  <details>
    <summary>BRCA+ → PARPi + ARPI</summary>
    <div class="tag parpi">PARPi</div><div class="tag arpi">ARPI</div>
    <p>Options: Olaparib + Abiraterone; Niraparib + Abiraterone; Talazoparib + Enzalutamide.</p>
    <div class="evidence">
      <strong>PROpel (2023)</strong> rPFS HR 0.29; OS HR 0.83 overall; BRCA OS HR 0.47 https://doi.org/10.1016/S1470-2045(23)00382-0DOI</a><br>
      <strong>TALAPRO-2 (2023)</strong> rPFS HR 0.45 HRR+ https://doi.org/10.1016/S0140-6736(23)01055-3DOI</a><br>
      <strong>MAGNITUDE (2023)</strong> rPFS HR 0.53 HRR+ <a class="doi" href="httpsO.22.01649DOI</a>
    </div>
  </details>
  <details>
    <summary>HRR– → ARPI or Docetaxel</summary>
    <div class="tag arpi">ARPI</div><div class="tag taxane">Taxane</div>
    <div class="evidence">
      <strong>COU-AA-302 (2013)</strong> Abiraterone rPFS HR 0.52; OS HR 0.81 https://doi.org/10.1016/S1470-2045(14)71205-7DOI</a><br>
      <strong>PREVAIL (2014)</strong> Enzalutamide rPFS HR 0.32; OS HR 0.77 https://doi.org/10.1056/NEJMoa1405095DOI</a><br>
      <strong>TAX-327 (2004)</strong> Docetaxel OS HR 0.79 https://doi.org/10.1056/NEJMoa040720DOI</a>
    </div>
  </details>
</section>

<!-- ADT + ARPI -->
<section class="card" id="adt-arpi">
  <h2>2) Prior CSPC: ADT + ARPI</h2>
  <details>
    <summary>BRCA+ → Olaparib monotherapy</summary>
    <div class="tag parpi">PARPi</div>
    <div class="evidence">
      <strong>PROfound (2020)</strong> rPFS HR 0.22; OS HR 0.63 https://doi.org/10.1056/NEJMoa1911440DOI</a>
    </div>
  </details>
  <details>
    <summary>HRR– → Docetaxel or Cabazitaxel</summary>
    <div class="tag taxane">Taxane</div>
    <div class="evidence">
      <strong>CARD (2019)</strong> Cabazitaxel vs ARPI switch rPFS HR 0.54; OS HR 0.64 https://doi.org/10.1056/NEJMoa1911206DOI</a>
    </div>
  </details>
</section>

<!-- ADT + Docetaxel -->
<section class="card" id="adt-docetaxel">
  <h2>3) Prior CSPC: ADT + Docetaxel</h2>
  <details>
    <summary>HRR+ → PARPi + ARPI</summary>
    <p>Same as ADT-only branch.</p>
  </details>
  <details>
    <summary>HRR– → ARPI or Cabazitaxel</summary>
    <div class="evidence">
      <strong>COU-AA-301 (2011)</strong> Abiraterone rPFS HR 0.66; OS HR 0.74 https://doi.org/10.1016/S1470-2045(12)70379-0DOI</a><br>
      <strong>AFFIRM (2012)</strong> Enzalutamide rPFS HR 0.40; OS HR 0.63 https://doi.org/10.1056/NEJMoa1207506DOI</a><br>
      <strong>TROPIC (2010)</strong> Cabazitaxel OS HR 0.70 https://doi.org/10.1016/S0140-6736(10)61389-XDOI</a>
    </div>
  </details>
</section>

<!-- Triplet -->
<section class="card" id="triplet">
  <h2>4) Prior CSPC: Triplet (ADT + ARPI + Docetaxel)</h2>
  <details>
    <summary>PSMA+ → 177Lu-PSMA-617</summary>
    <div class="tag radio">Radiopharm</div>
    <div class="evidence">
      <strong>VISION (2021)</strong> rPFS HR 0.40; OS HR 0.62 https://doi.org/10.1056/NEJMoa2107322DOI</a>
    </div>
  </details>
</section>

<!-- Special -->
<section class="card" id="special">
  <h2>Special Situations</h2>
  <details>
    <summary>Bone-only symptomatic → Radium-223</summary>
    <div class="tag radio">Radiopharm</div>
    <div class="evidence">
      <strong>ALSYMPCA (2013)</strong> OS HR 0.70 https://doi.org/10.1056/NEJMoa1213755DOI</a>
    </div>
  </details>
  <details>
    <summary>Indolent → Sipuleucel-T</summary>
    <div class="tag other">Cellular therapy</div>
    <div class="evidence">
      <strong>IMPACT (2010)</strong> OS HR 0.73 https://doi.org/10.1056/NEJMoa1001294DOI</a>
    </div>
  </details>
  <details>
    <summary>MSI-H/dMMR → Pembrolizumab</summary>
    <div class="tag immuno">Immunotherapy</div>
    <div class="evidence">
      <strong>KEYNOTE-158 (2020)</strong> ORR ~40%; OS median ~23.5 mo https://doi.org/10.1200/JCO.19.02105DOI</a>
    </div>
  </details>
</section>

<!-- NEPC -->
<section class="card" id="nepc">
  <h2>NEPC / AVPC</h2>
  <details>
    <summary>First-line</summary>
    <p>Cisplatin or carboplatin + etoposide; cabazitaxel + carboplatin for AVPC phenotype.</p>
  </details>
</section>

<p class="foot">Source: ASCO Guideline Update 2025; pivotal trials as linked. Educational use only.</p>
</div>
</div>
</body>
</html>
